comparemela.com

Latest Breaking News On - Healthcare 37 - Page 4 : comparemela.com

2023-11-12 | NDAQ:LXRX | Press Release | Lexicon Pharmaceuticals Inc

(2023-11-12 | NDAQ:LXRX) INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

United statesAlina cocuzzaRahul aggarwalFournier closecurlyquoteCraig granowitzScience session of the american heart associationLexicon pharmaceuticals incDrug administrationLexicon pharmaceuticalsAmerican heart associationExchange commissionScientific sessionsWomen closecurlyquoteLexicon closecurlyquoteConcomitant useInsulin secretagogues

2023-10-25 | NEO:CYBN | Press Release

(2023-10-25 | NEO:CYBN) Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program

United statesUnited kingdomDoug drysdaleCybin closecurlydoublequoteCybin closecurlyquoteTrademark officeCompany closecurlydoublequoteExchange commissionSmall pharma incCybin incCompany closecurlyquoteHealth canadaDrug administrationIntellectual propertyUnited states patentChief executive

2023-10-24 | NDAQ:APRE | Press Release | Aprea Therapeutics Inc

(2023-10-24 | NDAQ:APRE) Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

United kingdomCity ofUnited statesUniversity of pennsylvaniaAprea closecurlyquoteFiona simpkinsYap closecurlyquoteAprea closecurlydoublequoteTimothy yapMike moyerTimothya yapSecurities exchangeCleveland clinic foundationJohns hopkins universityTranslational researchExchange commission

2023-10-24 | NDAQ:ASLN | Press Release | Aslan Pharmaceuticals Ltd

(2023-10-24 | NDAQ:ASLN) ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

United statesAlex kaoukhovAshleyr robinsonJonathan silverbergAprilw armstrongEblasakimab closecurlyquoteDupilumab closecurlyquoteEmma thompsonExchange commission onPharmaceuticals nasdaqClinical research organizationLifesci advisorsSpurwing communicationsCompany closecurlydoublequoteEuropean academy of dermatologyGeorge washington university school of medicine

2023-10-23 | NDAQ:MRUS | Press Release

(2023-10-23 | NDAQ:MRUS) Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

United kingdomAndrew joeAlison schramZeno closecurlyquoteEarly access programMemorial sloan kettering cancer centerCorporate communicationsExchange commissionEuropean society for medical oncologyCompany closecurlydoublequotePrincipal investigatorEuropean societyMedical oncologyChief medical officerMerus closecurlyquoteMerus dock

vimarsana © 2020. All Rights Reserved.